Lonza eyes revenue growth this year after 2023 challenges, plans to close second biologics site in a month

After a year of navigating “shifting market dynamics,” Lonza reported on Friday it had a 7.9% sales revenue increase for 2023 compared to the previous year. But it is closing another biologics facility, this time in China, despite this division being one of the company’s main revenue drivers.

The manufacturer…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks